KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Consolidated Net Income (2017 - 2025)

Historic Consolidated Net Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $18.1 million.

  • Amneal Pharmaceuticals' Consolidated Net Income rose 5422.3% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 13929.75%. This contributed to the annual value of -$73.9 million for FY2024, which is 5155.42% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Consolidated Net Income is $18.1 million, which was up 5422.3% from $35.6 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Consolidated Net Income high stood at $35.6 million for Q2 2025, and its period low was -$240.1 million during Q2 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' median Consolidated Net Income value was -$2.4 million (recorded in 2022), while the average stood at -$14.7 million.
  • Data for Amneal Pharmaceuticals' Consolidated Net Income shows a peak YoY increase of 113541.32% (in 2023) and a maximum YoY decrease of 149508.11% (in 2023) over the last 5 years.
  • Amneal Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$20.4 million in 2021, then soared by 71.33% to -$5.9 million in 2022, then plummeted by 1495.08% to -$93.4 million in 2023, then surged by 77.75% to -$20.8 million in 2024, then soared by 187.26% to $18.1 million in 2025.
  • Its last three reported values are $18.1 million in Q3 2025, $35.6 million for Q2 2025, and $24.6 million during Q1 2025.